ReviewJACC. Basic to translational science2020
COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.
Review in JACC. Basic to translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Fatigue has a prominent impact on health lasting 12-weeks after COVID-19 infection.Malawi medical journal : the journal of Medical Association of Malawi · 2023Article
- Anti-inflammatory and anti-COVID-19 effect of a novel polyherbal formulation (Imusil) via modulating oxidative stress, inflammatory mediators and cytokine storm.Inflammopharmacology · 2022Article
- Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn.Gene reports · 2021Review
- Thrombosis, an important piece in the COVID-19 puzzle: From pathophysiology to therapy.Anatolian journal of cardiology · 2021Review
- Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils.Journal of the National Cancer Institute · 2021Article
- Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review.European journal of pharmacology · 2021Review
- A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management.Frontiers in pharmacology · 2021Review
- COVID-19 Fatigue: Not So Fast.JACC. Heart failure · 2020Article
- The National Institute of Allergy and Infectious Diseases Decision to Stop the Adaptive COVID-19 Trial: On Solid Ethical and Scientific Grounds.JACC. Basic to translational science · 2020Article
- The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population.Current oncology reports · 2020Review
- Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.Frontiers in cardiovascular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, the authors provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.